Phyxium Pharma in Conjunction With Oxygen Biotherapeutics, Inc. Announces New Evidence That Levosimendan Can Reduce Mortality in Heart Surgery Patients

Published: Oct 30, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

MORRISVILLE, N.C. & CHESTER, N.J.--(BUSINESS WIRE)--Phyxius Pharma, Inc. and Oxygen Biotherapeutics, Inc., (NASDAQ: OXBT), today announced that researchers at the Duke Clinical Research Institute (DCRI), part of the Duke University School of Medicine, recently published findings of a meta-analysis of multiple clinical trials that evaluated the use of levosimendan in patients undergoing heart surgery. The study aggregated and analyzed results from 14 independent clinical trials with a total of 1,155 patients. The published results showed that levosimendan was associated with reduced mortality (death) and other adverse outcomes including heart attacks during and after operation in patients with reduced heart function undergoing heart surgery. This research was recently published in the Journal of Cardiothoracic and Vascular Anesthesia as an "in Press" online version of the publication that precedes the final publication. A link to the online version of the publication is available here:

Help employers find you! Check out all the jobs and post your resume.

Back to news